BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, Mattern W, Schreiber M, Swartz R, Van Stone J. Multicenter trial of erythropoietin in patients on peritoneal dialysis. JASN 1995;5:1517-29. [DOI: 10.1681/asn.v571517] [Cited by in Crossref: 26] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database Syst Rev 2015;:CD011122. [PMID: 26671531 DOI: 10.1002/14651858.CD011122.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
2 Foley RN. Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 2008;13:405-14. [PMID: 18236154 DOI: 10.1007/s10741-008-9083-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
3 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
4 Hou YH, Yang FJ, Lai IC, Lin SP, Wan TT, Chang RE. Effects of Erythropoietin Payment Policy on Cardiovascular Outcomes of Peritoneal Dialysis Patients: Observational Study. JMIR Med Inform 2020;8:e18716. [PMID: 33331829 DOI: 10.2196/18716] [Reference Citation Analysis]
5 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Reference Citation Analysis]
6 Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56. [PMID: 22921639 DOI: 10.1053/j.ajkd.2012.07.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
7 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
8 Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One 2012;7:e43655. [PMID: 22952731 DOI: 10.1371/journal.pone.0043655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]